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BACKGROUND: Angiogenesis and haemostasis are closely linked within tumours with many haemostatic proteins regulating tumour
angiogenesis. Indeed we previously identified a fragment of human fibrinogen, fibrinogen E-fragment (FgnE) with potent anti-
angiogenic properties in vitro and cytotoxic effects on tumour vessels in vivo. We therefore investigated which region of FgnE was
mediating vessel cytotoxicity.
METHODS: Human dermal microvascular endothelial cells (ECs) were used to test the efficacy of peptides derived from FgnE on
proliferation, migration, differentiation, apoptosis and adhesion before testing the efficacy of an active peptide on tumour vasculature
in vivo.
RESULTS: We identified a 20-amino-acid peptide derived from the b chain of FgnE, b43–63, which had no effect on EC prolifera-
tion or migration but markedly inhibited the ability of activated ECs to form tubules or to adhere to various constituents of
the extracellular matrix – collagen IV, fibronectin and vitronectin. Furthermore, our data show that b43–63 interacts with ECs,
in part, by binding to avb3, so soluble avb3 abrogated b43–63 inhibition of tubule formation by activated ECs. Finally, when
injected into mice bearing tumour xenografts, b43–63 inhibited tumour vascularisation and induced formation of significant
tumour necrosis.
CONCLUSIONS: Taken together, these data suggest that b43–63 is a novel anti-tumour peptide whose anti-angiogenic effects are
mediated by avb3.
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Angiogenesis, the outgrowth of new capillaries from the existing
vasculature, is a multistep process that involves cell proliferation,
migration and differentiation (Folkman, 1995). It is a critical step
in tumour growth and is tightly regulated by a change in balance
between pro-angiogenic and anti-angiogenic factors in the local
environment. This often involves an upregulation in the expres-
sion of pro-angiogenic factors, such as vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF), platelet-derived
growth factor (PDGF) and type II fibroblast growth factor (FGF2)
(Folkman, 1995).
Many peptides derived from proteins involved in haemostasis
have been shown to regulate tumour angiogenesis (Daly et al,
2003). The blood clotting factor, fibrinogen (Fgn), is a large
(340 kDa) protein that contains three pairs of nonidentical
peptides: the a-, b- and g chains. These are arranged into three
domains, the two outer D-domains and a central E-domain
(Doolittle, 1981). Fibrinogen often accumulates in and around
leaky blood vessels in tumours and promotes tumour angiogenesis
by supporting cell adhesion, migration, proliferation and differ-
entiation of activated endothelial cells (ECs) (Zacharski et al,
1986). Fibrinogen can be digested in the body by plasmin and
when this occurs each Fgn molecule gives rise to two D fragments,
a number of small fragments, including a small peptide, b1–42
(the N terminus of the b-chain) and one 50-kDa E-fragment
(called fibrinogen E-fragment; FgnE) consisting of the N-terminal
regions of the a, b and g chains held together by disulphide bonds
(Bootle-Wilbraham et al, 2000).
We previously reported that FgnE is a potent anti-angiogenic
factor in vitro and vascular-damaging agent in vivo. It inhibits
the migration and differentiation of human ECs in response
to VEGF, EGF and FGF2 in vitro (Bootle-Wilbraham et al, 2000)
and is cytotoxic for activated ECs in vitro. These effects may
explain why FgnE selectively disrupts tumour endothelium,
causing widespread intravascular thrombosis and tumour necrosis
in vivo (Brown et al, 2002). We also showed that alphastatin,
a 24-amino-acid peptide fragment derived from the N terminus
of the a chain of FgnE, mimics many of the anti-angiogenic
effects of FgnE in vitro as well as its anti-vascular effects in vivo.
However, it is not cytotoxic for activated EC unlike FgnE (Staton
et al, 2004).
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We show here that another peptide found in the N terminus of
the b chain of FgnE (amino acids 43–63, Figure 1A) also has
minimal effects on EC viability but displays a pronounced ability
to inhibit the adherence of activated ECs to various components of
the extracellular matrix (ECM). Furthermore, we show that it does
so by binding to, and blocking ECM binding of, the integrin avb3
on ECs. Moreover, when injected into tumour-bearing mice, this
peptide inhibited tumour vascularisation and caused increased
levels of tumour necrosis.
MATERIALS AND METHODS
Cells
Adult human dermal microvascular endothelial cells (HuDMECs)
were obtained commercially (PromoCell, Heidelberg, Germany)
and cultured in microvascular endothelial cell growth medium
(EGM) with supplements (consisting of 0.4% CGS/H, 5% fetal calf
serum (FCS), 10 ngml1 EGF, 1 mgml1 hydrocortisone,
50 ngml1 amphotericin B, 50 mgml1 gentamicin). Cells were
grown at 371C in a 100% humidified incubator with the gas phase
of 5% CO2 and routinely screened for Mycoplasma. Human dermal
microvascular endothelial cells were used in the experiments until
they reached passage 6.
Proteins and peptides
All chemicals and reagents used were obtained from Sigma-Aldrich
(Dorset, UK) unless stated otherwise, and were of AnalaR or high-
performance liquid chromatography grade. Recombinant human
growth factors (VEGF165, EGF, PDGF, HGF and FGF2) were
purchased from R&D systems (Abingdon, UK), commercial
human FgnE and recombinant human avb3 were purchased from
Calbiochem (Merck, Darmstadt, Germany). b43–63 (ARPA-
KAAATQKKVERKAPDA), the control peptide, a scrambled form
of b43–63 (scrambled control peptide (bSC): RAQVPPAKKDAAR-
ATKAKAE) and other peptides derived from FgnE, including
alphastatin, were synthesised by GenScript Corporation (Piscat-
away, NJ, USA). In all experiments, FgnE was used at a final
concentration of 1 mM and the peptides used at 2 mM (which
corresponds to 1 mM FgnE).
Tubule formation assay
A total of 96-well plates were coated with 34 ml per well of growth
factor-reduced (GF-reduced) Matrigel (BD Biosciences, Bedford,
MA, USA). Human dermal microvascular endothelial cells were
serum depleted overnight in EGMþ 1%FCS and then seeded at
1.5 104 cells per well and allowed to attach for 45min. The
medium was then replaced with treatment medium
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Figure 1 (A) Schematic illustration of FgnE. Fibrinogen consists of two a chains, two b chains and two g chains. Alphastatin is the first 24 amino acids of
the N terminus of the a chains (a1–24) whereas b43–63 is the first 20 amino acids on the N terminus of the two b chains. 20-amino-acid peptides were
also generated from the C terminus of each chain representing the regions exposed upon plasmin cleavage of the original fibrinogen molecule. (B) Effects of
FgnE and derived peptides on the Matrigel assay. FgnE, alphastatin and b43–63 inhibit tubule formation in response to VEGF stimulation as measured by
number of tubules per field of view. FgnE was used at 1 mM, but the peptides were used at 2 mM as two copies of these peptides are present in a single FgnE
molecule. Data are presented as mean±s.e.m. *Po0.05 with respect to relevant control.
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(EGMþ 1%FCS), with/without peptides and/or GFs: VEGF
(10 ngml1), EGF (35 ngml1), FGF2 (25 ngml1), PDGF-BB
(25 ngml1) and hepatocyte growth factor (HGF; 100 ngml1).
Endothelial cells on this matrix migrated and formed tubules
within 6 h of plating (Kleinman et al, 1986). Tubule formation was
monitored at  40 magnification, using a light microscope (Nikon
Eclipse TS100, KingsTon upon Thames, Surrey, UK) and analysed
using the image analysis package, Scion Image (Frederick, MA,
USA) as previously described (Bootle-Wilbraham et al, 2000). For
the experiments using avb3, the b43–63 was incubated with
recombinant avb3 for 1 h before addition to the Matrigel assay.
Migration assay
The migration assay, adapted from Malinda et al (1999) involved
the use of a 48-well microchemotaxis chamber (Neuro Probe,
Cabin John, MD, USA) with 8 mm pore size polycarbonate
membranes (Neuro Probe) coated with 100 mgml1 human
collagen type I or IV. Vascular endothelial growth factor alone
(10 ngml1) or with peptides/FgnE was dissolved in EGMþ 1%
FCS and placed in the bottom wells. The membrane was then
positioned and 50 ml of 2.5 105 HuDMECs per ml (serum
depleted in EGMþ 1%FCS overnight) was added to the top
chamber. The chambers were incubated at 371C for 4.5 h then
migrated cells on the bottom surface were fixed and stained with
Hema ‘Gurr’ rapid staining kit (VWR, Poole, UK) and counted at
 40 magnification in three random fields per well in three
replicate wells and repeated three times.
Proliferation assay
To assess proliferation of HuDMECs, we used the BrdU assay
(Merck, Calbiochem, Beeston, UK), whereby BrdU is incorporated
into newly synthesised DNA strands of newly proliferating cells.
Human dermal microvascular endothelial cells were seeded into
96-well plates at 5 103 cells per well in EGM with 1% fetal bovine
serum and then incubated with FgnE and peptides for 24 h as
above. BrdU label was added for 6 h and then cells were
permeabilised and incubated with antibodies according to
manufacturers’ instructions. The absorbance was read at 450 nm,
using an Anthos Labtec Instruments (Salzburg, Austria) plate
reader.
Cell viability assays
Human dermal microvascular endothelial cells were seeded into a
48-well plate at a density of 2 105 cells per well and then serum
starved for 24 h in EGMþ 1%FCS. The cells were then incubated
for 24 h with b43–63 or bSC before a 20-min incubation with
1 ml of fluorescein isothiocyanate (FITC)-conjugated Z-VAD-FMK
(carbobenzoxy-valyl-alanyl-aspartyl-fluoromethylketone; Promega,
Southampton, UK), a cell permeable, irreversible pan-caspase
inhibitor that allows in situ labelling of activated caspases. The
cells were then washed 3 with FACS buffer (phosphate-buffered
saline (PBS) with 0.1% BSA), trypsynised and finally 1 ml
propidium iodide (PI, 50 mgml1) was added to measure dead
cells. A total of 10 000 cells were analysed using FACScan (FL1 and
FL2 filters – 530 and 585 nm). The distribution of live, apoptotic
and late apoptotic/necrotic cells were analysed based on distribu-
tion of staurosporine-treated (400 nM, 2 h) cells that were used as
the positive control for apoptosis/necrosis. Live cells had no stain
at all, early apoptosis cells were stained with FITC stain only, late-
stage apoptotic cells with FITC and PI.
Western blotting for phosphorylated Akt
Human dermal microvascular endothelial cells were plated down
into six-well plates and grown to near confluence before serum
depletion (EGMþ 1%FCS) overnight. The cells were then incu-
bated with peptides for 3 h before a 5-min incubation with VEGF
(10 ngml1). After treatment the cells were washed twice in PBS
and suspended in a triple cell lysis buffer (50 nM Tris-HCI (pH 8.5),
150 nM NaCl, 0.1% SDS, 1% nonident-P40, 0.5% sodium deox-
ycholate and a complete protease inhibitor tablet (Roche,
Mannheim, Germany)) and placed on ice for 20min before
centrifugation. Protein concentrations of the supernatants were
determined using the bicinchoninic acid assay. Equal amounts of
protein extracts (20 mg) were separated by SDS–polyacrylamide gel
electrophoresis, electrotransferred to nitrocellulose membranes
and exposed to anti-Akt or phospho-Akt (BD Biosciences).
Immunoreactive bands were detected by enhanced chemilumines-
cence (Amersham, Little Chalfont, Buckinghamshire, UK), and
band intensity quantified using densitometry software (Bio-Rad,
Hemel Hempstead, Hertfordshire, UK).
Cell adhesion assay
A total of 96-well plates were coated overnight with 10 mgml1
human collagen type IV (Sigma-Aldrich), 5 mgml1 human
fibronectin (Merck) or 0.5 mgml1 human vitronectin (Invitrogen,
Paisley, Renfrewshire, UK), then washed with PBS. Meanwhile,
HuDMECs were serum depleted in EGMþ 1%FCS overnight then
lifted using non-enzymatic cell dissociation solution, and incu-
bated for an hour at 371C with VEGF (10 ngml1) in the absence or
presence of FgnE, alphastatin, b43–63 or bSC. Matrix-coated 96-
well plates were seeded with 100ml of cell suspension (5000 cells
per well) together with noncoated plates (referred to as ‘plastic
control’). After 1 h incubation at 371C the wells were washed twice
with PBS, and any cells that remained attached were fixed with
methanol and stained with methyl blue. Stained cells were
photographed (at  40 magnification) and counted in three
different fields of view per well.
As integrins mediate cell adhesion to ECM proteins – and the
only integrin known to mediate adhesion to all three ECM proteins
studied is avb3 – the role of this integrin in mediating the
inhibiting effect of b43–63 on ECs was investigated. Moreover, the
b chain of Fgn is thought to bind to heparin sulphate
proteoglycans so the effect of heparin on cell adhesion was also
investigated. 96-well plates were coated with 100 ml of b43–63 or
bSC overnight (10mgml1), then washed and pre-incubated for 1 h
with or without recombinant avb3 or heparin before addition of the
HuDMECs (pre-incubated with VEGF). The cells were allowed to
adhere for 1 h before washing and staining as before.
Direct binding assays
96-well plates were coated overnight with PBS (plastic control)
10mgml1 b43–63, 10mg/ml bSC (negative control) or 0.5 mgml1
vitronectin (positive control), then washed and blocked with 5%
BSA in PBS for 1 h. The wells were then washed, incubated with
recombinant avb3 for 1.5 h, then washed and incubated with anti-
avb3 antibody for 1.5 h, then washed and incubated with anti-
mouse-HRP-conjugated secondary antibody for a further hour and
finally washed and incubated with OPD for 15min before reading
on an ELISA plate reader (450 nm). Controls included wells coated
and treated with everything except avb3 (data shown) and
nonspecific binding to plastic was subtracted from the final results.
Tumour xenograft studies
All experiments were performed under HO Project Licence
Number PPL40/3110 and conformed to the United Kingdom Co-
ordinating Committee on Cancer Research Guidelines for the
Welfare of Animals in Experimental Neoplasia. The CaNT murine
mammary adenocarcinoma is a transplanted tumour model,
derived from a spontaneous tumour and is maintained in vivo
Anti-angiogenic effects of b43–63
E Krajewska et al
596
British Journal of Cancer (2010) 102(3), 594 – 601 & 2010 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
by the transfer of tumour cells between mice (Collingridge and
Chaplin, 2001). CBA/Gy mice (Gray cancer Institute, Northwood,
UK) were anaesthetised by isofluorane inhalation and inoculated
subcutaneously with 106 viable CaNT tumour cells. Tumour volume
was determined at regular intervals by caliper measurement
(accurate to 0.1mm) in two dimensions as described previously
(Brown et al, 2002) using the equation: volume¼ (a2 b)/2, where
a is the smaller and b the larger diameter of the two. When tumours
had grown to 100–150mm3, mice were injected i.p. daily for
10 days with b43–63 (0.084mgkg1) or vehicle (PBS).
After 10 days, mice were killed and tumours (and various
normal tissues) excised, divided into two halves and fixed in either
(1) 10% neutral buffered formalin or (2) zinc-based fixative
(Beckstead, 1994), then processed into paraffin wax. Formalin-
fixed sections were stained for H&E and tumour necrosis assessed
semi-quantitatively using a Chalkley grid method (% necrosis)
(Brown et al, 2002). Zinc-fixed sections were exposed to a rat
monoclonal anti-murine CD31 (1 : 100; Pharmingen, San Diego,
CA, USA) specific for ECs, for 60min at room temperature, and
immunoreactivity detected using the ABC rat elite kit (Vector
Laboratories, UK) and diaminobenzidine. Vessels were then
counted per field of view ( 40) for all tumours.
Statistical analysis
All experiments were performed at least three times, and data were
analysed using the Mann–Whitney U-test, a nonparametric test
that does not assume a Gaussian distribution in the data being
analysed. Pp0.05 was taken as significant.
RESULTS
Our previous experiments showed that 1 mM FgnE inhibited
differentiation of ECs into tubule-like structures when plated on
Matrigel in the presence or absence of VEGF. In contrast the
parent Fgn molecule did not cause inhibition (Bootle-Wilbraham
et al, 2000). We therefore initially synthesised peptides derived
from the termini of the FgnE chains exposed by plasmin cleavage
(Figure 1A) for testing in the Matrigel assay (Figure 1B). Of the
four peptides tested, only b43–63 inhibited EC differentiation and
was therefore subjected to more thorough investigation.
Indeed Figure 2 shows that b43–63, but not the control peptide
(scrambled b43–63), significantly (Po0.05) inhibited the length,
number and area of tubules formed by EC activated by the five
prominent angiogenic factors found in tumours (VEGF, PDGF-BB,
EGF, FGF2 and HGF) on GF-reduced Matrigel, although b43–63
showed only minimal inhibition of EGF-induced tubule formation.
The inhibitory effects of b43–63 were seen for both GF and non-
GF activated cells. At first this may appear to suggest that ECs do
not need to be ‘activated’ by a stimulant like VEGF to respond to
these two agents. However, GF-reduced Matrigel does itself act as a
stimulant/activator inducing ECs to form tubules in the absence of
exogenous GFs.
Our previous experiments have shown that 1 mM FgnE (the
parent molecule of b43–63) is cytotoxic for GF-activated ECs
(Bootle-Wilbraham et al, 2000). We therefore wished to ascertain
whether the inhibitory effects of b43–63 on tubule formation was
due to a similar cytotoxic effect in culture. Figure 3A shows that
b43–63 slightly abrogated the pro-survival effect of VEGF on ECs,
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Figure 2 b43–63 also inhibits tubule formation by ECs in response to four other pro-angiogenic growth factors, PDGF, FGF2, EGF and HGF, in vitro.
(A) Length, (B) number and (C) area covered by tubules formed by HuDMECs in response to the above growth factors in the absence or presence
of b43–63 or scrambled b43–63 (bSC) used at 2mM. *Po0.05 with respect to relevant control group, ^Po0.05 with respect to control No-GF group.
All data are means±s.e.m. Data are representative of three replicate experiments. (D) Typical appearance of VEGF-induced tubules (in wells of a 96-well
plate) in the presence of (i) VEGF alone, (ii) VEGF þ 2 mM b43–63 and (iii) VEGF þ 2mM bSC.
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inducing a marginal (o10%) increase in late-stage apoptosis/
necrosis in VEGF-activated ECs. This effect was not seen when
scrambled b43–63 was used. To investigate whether this cytotoxic
effect was mediated through the PI3K/Akt pathway, we undertook
western blotting analysis of phosphorylated Akt. Although VEGF
stimulated Akt phosphorylation, this was only marginally (non-
significantly) inhibited by b43–63 (Figure 3B) and unaffected
by bSC.
These findings suggested that the marked inhibitory effects of
b43–63 in the tubule formation assay (Figure 2) were not due to
induction of extensive EC death. Moreover unlike FgnE and
alphastatin, b43–63 had no effect on either EC migration or
proliferation (Figure 3C and D), suggesting an alternative
mechanism of action for b43–63.
We then investigated whether b43–63 might inhibit angio-
genesis by inhibiting VEGF-activated adhesion of ECs to ECM
proteins (an important step in the angiogenic pathway (Eliceiri,
2001)), namely collagen IV, fibronectin and vitronectin (Hynes,
2007; Mundel and Kalluri, 2007). Endothelial cells were pre-
incubated with test peptides and VEGF for 1 h, and then allowed to
adhere for a further hour (Delaney et al, 2006). Whereas both FgnE
and alphastatin significantly (Po0.05) inhibited EC adhesion to
collagen IV, b43–63 significantly (Po0.05) inhibited EC adhesion
to all three ECM proteins. This effect was not seen with scrambled
b43–63 (Figure 4A).
Endothelial cells adhere to the ECM largely through cell-surface
heparin sulphate proteoglycans and integrins and avb3 is the
only integrin to bind to all three of ECM proteins used here.
We therefore investigated whether b43–63 might bind to heparin
or avb3 and thus block EC adhesion to the ECM. Activated EC were
seen to adhere to b43–63 in a manner that was significantly
(Po0.05) but not completely blocked by the addition of exogenous
recombinant human avb3, a noncovalent heterodimer containing
the ligand binding extracellular portion of human avb3 (Figure 4B).
Moreover direct binding studies confirmed that recombinant avb3
binds to vitronectin (a positive control) and b43–63 in a solid-
phase assay (Figure 4C). In contrast heparin did not significantly
affect EC adhesion to b43–63 (Figure 4B). To further investigate
the possibility of b43–63 mediating its effects by avb3, we incu-
bated b43–63 with recombinant avb3 before use in the Matrigel
assay. In this experiment recombinant avb3 alone had no effect on
tubule formation, but completely ablated the b43–63 inhibition of
tubule formation (Figure 4D).
Finally, we investigated whether b43–63 could inhibit tumour
growth and angiogenesis in vivo using the CaNT murine mammary
adenocarcinoma model. Control tumours grew steadily over the
10-day injection period, whereas b43–63 treated tumours showed
nonsignificantly slower growth (being 16% smaller by day 10;
Figure 5A). The experiment could not be extended beyond this
point as the control tumours started to ulcerate and the mice
had to be killed. b43–63 injections were well tolerated in vivo
with no significant effect on body weight or the general well
being of the animals. A significant reduction in the number
of vessels (Po0.02) within the b43–63 treated tumours was
observed (Figure 5B and D). Moreover, a central area of necrosis
was evident in both control and b43–63 treated tumours, but
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Figure 3 Effects of b43–63 on (A) viability, (B) Akt phosphorylation, (C) migration and (D) proliferation of HuDMECs in response to VEGF in vitro.
All data are means±s.e.m. (A) Flow cytometry profiles showing (i) late stage apoptosis and necrosis (ii), apoptosis (iii) and live cells in control media or in
the presence of b43–63 or bSC. (iv) graph showing % live cells in presence or absence of VEGF in response to peptide treatment. (B) Western blot analysis
of Akt phosphorylation in the presence or absence of VEGF (10 ngml1) in response to peptide treatment. (i) Scans of original blots for phosphorylated Akt
and total Akt. (ii) Densitometry analysis showing slight inhibition in phosphorylation of Akt in the presence of VEGF (10 ngml1) in response to b43–63.
(C) HuDMEC migration across a collagen-coated filter in response to medium alone (control) or medium containing 10 ngml1 VEGF. (D) HuDMEC
proliferation in response to medium alone (control or medium containing VEGF (10 ngml1)). *Po0.05 with respect to relevant control group. All data are
the average of three repeat experiments.
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was significantly (Po0.03) larger in b43–63 treated mice
(Figure 5B and C).
DISCUSSION
Complex interactions between microvascular ECs and factors in
the local microenvironment (eg GFs, ECM constituents) regulate
angiogenesis. In response to such signals, ECs degrade surround-
ing matrices, proliferate, migrate and fully differentiate to form
new capillary tubules. In vitro models of these various steps are
invaluable in gaining insights into the mode of action of newly
identified angiogenesis regulators. We have used an array of such
assays to fully characterise the anti-angiogenic effects of a peptide
derived from human Fgn, b43–63. We show that although b43–63
inhibited EC differentiation as measured by tubule formation in
response to multiple GFs, it had no effect on their migration or
proliferation, and only a marginal effect on viability. It also
inhibited the adhesion of VEGF-activated ECs to a number of
angiogenesis-regulating ECM proteins – an effect involving
blockade by the b43–63 peptide of avb3 on the surface of activated
ECs.
Interestingly, although b43–63 inhibited the effects of multiple
GFs (VEGF, PDGF, HGF and FGF2) on ECs, it had much less of an
effect on their activation by EGF. The overlapping signalling
pathways used by VEGF, PDGF, HGF and FGF2 suggests that b43–
63 may inhibit ECs by the suppression of signalling molecules that
are common to these four GFs, such as PI3K/Akt and/or FAK/
Paxillin (focal adhesion). Alteration of FAK/Paxillin association
and phosphorylation by b43–63 would be highly likely to result in
reduced GF-induced migration (Saito et al, 2008) – an effect that
was not seen with the peptide (Figure 3B). The marginal reduction
in cell survival seen with b43–63 (Figure 3A), and the minimal
effect seen on Akt phosphorylation suggests that it also does not
profoundly modulate the PI3K/Akt pathway in ECs (which is
known to regulate EC survival and apoptosis (Kucharzewska et al,
2009)). Further studies are now warranted to identify the point of
interaction between the signalling pathway activated by b43–63
receptor binding and those activated by VEGF, PDGF, HGF and
FGF2.
The fact that b43–63 inhibited adhesion of VEGF-activated ECs
to all three ECM proteins used suggests that this may represent at
least part of the mechanism by which it inhibits tubule formation
by VEGF-activated ECs (as GF-reduced Matrigel contains 30%
collagen IV; http://www.bdbiosciences.com). However, blocking of
adhesion is unlikely to be the only mechanism involved as b43–63
failed to inhibit migration of ECs across collagen type I or IV
coated filters in our migration assays, and had a pro-apoptotic
effect on VEGF-stimulated ECs in the absence of any ECM
proteins.
Endothelial cells express a wide array of integrins that mediate
their interaction with, and activation by, ECM components and
GFs. Integrin avb3 is the only known integrin to bind to all three
ECM proteins tested in our adhesion assays (Mizejewski, 1999;
Ru¨egg and Mariotti, 2003), and moreover avb3 is known to interact
with the receptors for all the GFs tested and increases angiogenesis
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when bound to ECM protein ligands (Soldi et al, 1999; Borges et al,
2000; Sahni and Francis, 2004; Kemp et al, 2006; Ellis et al, 2007).
However, when soluble ligands bind/activate avb3, the ability of
various GFs (eg VEGF, FGF2, PDGF and HGF) to activate their own
receptors is inhibited; for example, interaction of soluble ligands
with avb3 can reduce VEGF-stimulated VEGF-R2 tyrosine phos-
phorylation (Soldi et al, 1999). Interestingly, although EGFR does
bind to avb3, activation of HuDMECs by EGF does not require the
binding of avb3 to EGFR (Ellis et al, 2007), which may explain why
b43–63’s effects on EGF are more limited compared to the other
GFs (ie where avb3 binding to receptors is required for full
activation; Borges et al, 2000). We therefore hypothesised that
interaction of b43–63 with avb3 on the surface of ECs could
explain its ability to inhibit multiple GF pathways stimulating EC
differentiation. Moreover, some studies suggest that when avb3 is
occupied by a soluble ligand (such as b43–63) it can mediate pro-
apoptotic signals (Maeshima et al, 2001), which may explain the
slight increase in apoptosis with b43–63.
The avb3 integrin is known to bind to the RGD
572574 sequence
on the a chain of whole Fgn (Yokoyama et al, 1999). However,
b43–63 is derived from the b rather than the a chain of Fgn, and
does not contain an RGD or RGD-like sequence (Figure 1). It is
now recognised that proteins and peptides can bind to avb3 by
non-RGD regions; for example, tumstatin, an inhibitor of tumour
angiogenesis induces apoptosis of ECs by an avb3 integrin-
dependent manner (Maeshima et al, 2002), using non-RGD
sequences (Maeshima et al, 2000), although b43–63 bears no
homology with the tumstatin avb3 binding regions. Our experi-
ments show recombinant avb3 binds directly to b43–63, partially
inhibits the binding of HuDMEC to b43–63, and incubation of
recombinant avb3 with b43–63 before the Matrigel experiment
ablates the ability of b43–63 to inhibit EC differentiation/tubule
formation. Therefore, taken together, our data suggest that one
possible receptor for b43–63 could be a non-RGD binding
sequence on the avb3 integrin.
Although studies investigating Fgn have shown that b43–57
(contained within b43–63) is a heparin binding site (Yakovlev
et al, 2003), and heparin sulphate proteoglycans are used as co-
receptors for the GFs (except EGF) (Neufeld et al, 1994; Chua et al,
2004; Kemp et al, 2006), binding studies have shown that the
affinity of b43–57 for heparin is relatively low compared to
dimerised b15–66 peptides (Yakovlev et al, 2003), suggesting that
dimerisation is essential for high-affinity HS binding. As the b43–
63 peptide used in our study is not dimerised, it is unlikely that
such binding would mediate the effects seen with b43–63. Indeed
our data show that heparin had no effect on the binding of
HuDMECs to b43–63 (Figure 4B) suggesting that heparin binding
is not involved in mediating b43–63 activity.
Interestingly, in contrast to FgnE and alphastatin that inhibit
tumour growth by causing vascular damage and an increase in
intravessel thrombosis within the tumours rather than by anti-
angiogenic mechanisms (Brown et al, 2002; Staton et al, 2004),
b43–63 caused a significant decrease in tumour vascularisation (ie
was anti-angiogenic) without any evidence of thrombosis. This
decrease in vessel counts could account for the increase in tumour
necrosis, and decrease in tumour growth and suggests that should
the control tumours not have ulcerated and therefore the
experiment be continued beyond 10 days treatment, a greater
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effect on tumour growth would have been observed. The effects
observed on blood vessels is similar to that reported using known
avb3 antagonists (RGD-containing drugs) where vessel counts were
reduced, but there were no observed effects on vascular
thrombosis (Park et al, 2008), adding further evidence that avb3
may be a receptor for b43–63.
In sum, our data show for the first time that a novel, 20-amino-
acid peptide derived from the b chain of human Fgn, has a unique
ability to inhibit the angiogenic responses of ECs to multiple GFs
such as VEGF, FGF2, PDGF and HGF in vitro, and to inhibit
tumour vascularisation in vivo. This appears to involve, in part, the
binding of b43–63 to avb3 integrin and the reduced ability of
activated ECs to adhere to various ECM proteins. Further studies
are now warranted to better understand the mode of action of this
new agent so that its efficacy in anti-angiogenic therapies can be
maximised.
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